Oxford Biomedica Solutions
Samuel Adjei is an accomplished scientist with a strong background in analytical development and computational biology, currently holding the position of Scientist 1 at Oxford Biomedica since March 2023. Prior experience includes roles at Homology Medicines, Inc. as a Scientist 1 and Senior Research Associate in Molecular Biology & Genomics, as well as serving as a Research Scientist at South Dakota State University, where significant contributions were made in cloning and purifying proteins and studying protein interactions. Samuel Adjei also has experience in academic settings, having worked as a Graduate Teaching Assistant and Teaching and Research Assistant, and holds a PhD in Biochemistry, an M.S in Data Science, and a Bachelor's degree in Molecular Biology and Biotechnology. Ongoing education includes a Professional Certificate in Machine Learning Engineering and Artificial Intelligence from UMass Global.
This person is not in the org chart
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.